论文部分内容阅读
目的：探讨多药耐药基因（ＭＤＲ_１）阳性表达与卵巢恶性肿瘤耐药产生、化疗疗效及生存率的关系。方法：应用逆转录一多聚酶链反应（ＲＴ－ ＰＣＲ）检测 ２９例卵巢恶性肿瘤组织标本 ＭＤＲ_１阳性表达，并用β_２微球蛋白（β_２Ｍ）基因作内对照，对２９例卵巢恶性肿瘤患者术后化疗疗效观察及生存率进行随访。结果：卵巢恶性肿瘤手术切除组织标本ＭＤＲ_１阳性表达为５５．２％，其中术前化疗的病例为５例，占ＭＤＲ_１阳性表达的３１．３％。 ＭＤＲ_１阳性表达在患者年龄、临床期别、病理类型及分化程度等方面差异无显著性。在化疗有效组中，ＭＤＲ_１阳性表达和ＭＤＲ_１阴性分别为４３．８％和８４．６％，ＭＤＲ_１阴性和ＭＤＲ_１阳性表达的５年生存率分别为４６．２％和６．３％，两者差异均有显著性。结论：卵巢恶性肿瘤组织中ＭＤＲ_１阳性表达与临床化疗耐药有关，并影响其生存率，ＭＤＲ_１检测可作为判断恶性肿瘤预后的客观指标之一。
Objective: To investigate the relationship between multidrug resistance gene (MDR_1) expression and drug resistance, chemotherapy efficacy and survival rate in ovarian cancer. Methods: RT-PCR was used to detect the positive expression of MDR-1 in 29 cases of ovarian malignant tumors and 29 cases of ovarian cancer were treated with β_2 microglobulin (β_2M) Observation and survival rate were followed up. Results: The positive expression of MDR_1 in surgical specimens of ovarian cancer was 55.2%. Among them, 5 cases were preoperative chemotherapy, accounting for 31.3% of MDR_1 positive. The positive expression of MDR_1 in patients with age, clinical stage, pathological type and degree of differentiation was no significant difference. In the chemotherapy-effective group, the 5-year survival rates of MDR-1 and MDR-1 were 43.8% and 84.6% respectively, while those of MDR-1 and MDR-1 were 46.2% and 6.3% respectively All were significant. Conclusion: The positive expression of MDR_1 in ovarian cancer is related to the resistance to chemotherapy and its survival rate. The detection of MDR_1 can be used as one of the objective indexes to judge the prognosis of malignant tumor.